Acıbadem University School of Medicine, Department of Endocrinology, İstanbul, Turkey.
Koç University Hospital, Department of Neurosurgery, Istanbul, Turkey.
J Clin Neurosci. 2021 Apr;86:145-153. doi: 10.1016/j.jocn.2021.01.025. Epub 2021 Feb 4.
Gamma Knife radiosurgery (GKRS) for lactotroph adenomas (LAs) or prolactinomas is limited due to the effectiveness of medical treatments and surgery. Cases who are refractory to medical treatment and/or surgery may be managed with GKRS. We aimed to describe the effectiveness of GKRS for high-risk lactotroph adenomas (HRLAs) and LAs that were medically and surgically refractory. We analyzed our series of patients with HRLAs and LAs who were managed with GKRS following failed medical treatment and surgery and who had at least three years of follow-up. A total of 52 patients (22 HRLAs and 30 LAs) were included in the analysis of radiological, endocrine, and clinical outcomes. Radiological control was achieved in 68.2% of subjects in the HRLA group and 96.7% of subjects in the LA group. Hormonal control was achieved in 68.2% of patients in the HRLA group and 80% of patients in the LA group. On univariate analysis, hormonal control was significantly associated with pre-treatment volume (p = 0.007), higher margin dose (p = 0.002) and Ki-67 proliferative index (p = 0.007). Complications involved new pituitary hormone deficiencies in 19.2% of patients and asymptomatic peripheral visual field defect in 1.9% of patients. To the best of our knowledge, this is the first study to examine the effectiveness of GKRS in LAs and HRLAs, with the highest median follow-up in the literature. High hormonal control rate, even in HRLAs, and lower complication rates suggest that GKRS should be part of the techniques for managing treatment refractory LAs.
伽玛刀放射外科(GKRS)治疗催乳素腺瘤(LAs)或泌乳素瘤的效果受到医学治疗和手术的限制。对于那些对药物治疗和/或手术无反应的病例,可能需要采用 GKRS 进行治疗。我们旨在描述 GKRS 治疗药物和手术治疗无效的高危催乳素腺瘤(HRLAs)和 LA 的效果。我们分析了我们一系列接受 GKRS 治疗的 HRLAs 和 LA 患者,这些患者在药物和手术治疗失败后,至少有 3 年的随访。共有 52 例患者(22 例 HRLAs 和 30 例 LAs)纳入放射学、内分泌和临床结局的分析。在 HRLA 组中,68.2%的患者实现了放射学控制,LA 组中 96.7%的患者实现了放射学控制。HRLA 组中 68.2%的患者实现了激素控制,LA 组中 80%的患者实现了激素控制。单因素分析显示,激素控制与治疗前体积(p=0.007)、较高的边缘剂量(p=0.002)和 Ki-67 增殖指数(p=0.007)显著相关。并发症包括 19.2%的患者出现新的垂体激素缺乏,1.9%的患者出现无症状的周边视野缺损。据我们所知,这是第一项研究 GKRS 在 LA 和 HRLA 中的有效性的研究,文献中随访时间最长。高激素控制率,即使在 HRLAs 中,以及较低的并发症发生率表明 GKRS 应该是治疗难治性 LA 的技术之一。